MEG-01

Megakaryoblast from Chronic myelogenous leukemia (CML)

Cell Type:
Megakaryocyte
Tissue Origin:
bone marrow
Species:
human
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cell Characteristics:
Suspension

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
SE EN-102 1e6 74% ±1 79% ±17 Plasmid (general) 2 µg 100 µl 4D X-Unit
SE EN-102 2e5 67% ±1 61% ±4 Plasmid (general) 0.4 µg 20 µl 4D X-Unit
C X-005 1e6 80% ±4 66% ±2 Plasmid (general) 2 µg 100 µl I/II/2b

Citations

Categories:
Transfection 
Authors:
Sawada T, Nishiyama C, Kishi T, Sasazuki T, Komazawa-Sakon S, Xue X, Piao JH, Ogata H, Nakayama JI, Taki T, Hayashi Y, Watanabe M, Yagita H, Okumura K, Nakano H 
In:
J Biol Chem (2008) epub: online 
Categories:
Transfection 
Authors:
Shen GQ, Li L, Girelli D, Seidelmann SB, Rao S, Fan C, Park JE, Xi Q, Li J, Hu Y, Olivieri O, Marchant K, Barnard J, Corrocher R, Elston R, Cassano J, Henderson S, Hazen SL, Plow EF, Topol EJ, Wang QK 
In:
Am J Hum Genet (2007) 81(4): 780-91